Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures
On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…
European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19
On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…
Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19
On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…
CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics
On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…
Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
Ultragenyx announced plans to build large-scale gene therapy manufacturing facility for rare diseases
On Nov. 9, 2020, Ultragenyx announced that it planned to build a new large-scale gene therapy manufacturing facility…
Single-cell study of Ebola highlighted virus’s lethal maneuvers
On Nov. 6, 2020, in a study published in Cell, the researchers identified antiviral defense genes that the…
AquaBounty announced Mayfield, Kentucky as location for planned 10,000 metric ton salmon farm
On Oct. 29, 2020, AquaBounty Technologies announced that it had identified Mayfield, Kentucky as the potential location for…
Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
UK MHRA began rolling review of Moderna’s mRNA COVID-19 vaccine
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Additional COVID-19 related genes ﾖ both helpful and harmful ﾖ revealed in massive screen
On Oct. 27, 2020, researchers at Yale University and the Broad Institute of MIT and Harvard screened hundred…
Moderna announced supply agreement with Qatar for mRNA vaccine against COVID-19
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
RNA ‘ticker tape’ records gene activity over time
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
DARPA awarded Moderna $56 Million to enable small-scale, rapid mobile manufacturing of vaccines and therapeutics
On Oct. 8, 2020, Moderna announced an agreement for a commitment of up to $56 million from the…
HHS funded development of needle-free vaccine administration technology
On Oct. 6, 2020, the U.S. Department of Health and Human Services announced funding of a patch that…
Broad and Brigham and Women’s Hospital launched COVID-19 surveillance study
On Oct. 6, 2020, clinicians and researchers from Brigham and Women’s Hospital, the Broad Institute of MIT and…
Johnson & Johnson completed acquisition of Momenta Pharmaceuticals for $65 billion
On Oct. 1, 2020, Johnson & Johnson announced it had successfully completed its acquisition of Momenta Pharmaceuticals, a…
Moderna announced publication in The NEJM of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Sept. 29, 2020, Moderna announced the publication of the second interim analysis of the open-label Phase 1…
MIT and the Broad Institute Developed Rapid test for COVID-19 showed improved sensitivity
On Sept. 17, 2020, researchers announced a CRISPR-based test developed at MIT and the Broad Institute that can…
Elevated levels of a blood clotting factor linked to worse outcomes in severe COVID-19
On Sept. 9, 2020, Harvard Medical School investigators at Massachusetts General Hospital reported that patients hospitalized with severe…
Biopharma leaders united to stand with science
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
Broad Institute provided COVID-19 screening for students, faculty and staff at more than 100 colleges and universities
On Sept. 2, 2020, Broad Institute of MIT and Harvard announced it had partnered with 108 public and…
Moderna confirmed discussions with the MHLW to supply Japan with 40 million doses of mRNA vaccine against COVID-19
On Aug. 28, 2020, Moderna confirmed that the Company was engaged in discussions with the Ministry of Health,…
Rapid diagnostic detected Lassa and Ebola in real-time
On Aug. 26, 2020, researchers announced an inexpensive, sensitive, CRISPR-based tests diagnose two deadly viruses in settings with…
How SARS-CoV-2 spread across greater Boston during pandemic’s first wave
On Aug. 25, 2020, data from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, the Massachusetts…
Genomic analysis revealed many animal species may be vulnerable to SARS-CoV-2 infection
On Aug. 24, 2020, humans are not the only species facing a potential threat from SARS-CoV-2, the novel…